News
On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...
Review the current valuation for Regeneron Pharmaceuticals Inc (REGN:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
Read about Regeneron Pharmaceuticals Inc (REGN:XNAS) stock and today's latest news and financial updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback